Repository logo
 
Publication

Retrospective study of cisplatin plus radiotherapy toxicities in locally advanced squamous cell carcinoma of the head and neck – ReCisTT study

2024-10-14Journal article Open access
Simple item page
dc.contributor.authorGomes, Ana
dc.contributor.authorCastro, Gilberto
dc.contributor.authorOliveira, Thiago Bueno de
dc.contributor.authorColmenero, Ana Medina
dc.contributor.authorRibeiro, Leonor
dc.contributor.authorPsyrri, Amanda
dc.contributor.authorMagné, Nicolas
dc.contributor.authorSerrahima, Maria Plana
dc.contributor.authorMarinho, Joana
dc.contributor.authorGiglio, Raul
dc.contributor.authorRey, Leticia Iglesias
dc.contributor.authorAngel, Martín
dc.contributor.authorMacedo, Ana
dc.date.accessioned2024-12-04T11:09:58Z
dc.date.available2024-12-04T11:09:58Z
dc.date.issued2024-10-14
dc.description.abstractIntroduction Squamous cell carcinoma of the head and neck (SCCHN) is a multifactorial disease involving genetic and environmental factors representing one of the most frequent cancer-related deaths worldwide. Tobacco and alcohol use account for most SCCHN, while a growing subset of oropharyngeal cancers is causally associated with human papillomavirus (HPV) infection. Despite improvements in overall survival, patients with HPV-negative locally advanced (LA) SCCHN continue to have a poor prognosis. For these patients, the standard of care is radiotherapy with concurrent chemotherapy (RCT).Methods This retrospective, multicenter, and observational study analyzed the treatment compliance of 326 patients with LA-SCCHN who underwent RCT between January 1st, 2014, and June 30th, 2017. This study also evaluated the potential factors associated with treatment compliance, the compliance impact on clinical response, and the main toxicities experienced by patients.Results A total of 274 (84%) patients were compliant and received the planned dose of cisplatin. Overall, 957 adverse events were reported in 98.2% of patients during the study. The overall response rate was 80.2%, with 60.4% of patients achieving a complete response.Discussion Despite the high treatment compliance, 62.6% of adverse events reported were related to cisplatin. Identifying risk factors associated with non-compliance could enable physicians to identify ineligible patients for cisplatin-based RCT and prevent patients from receiving inadequate treatment leading to severe adverse events.eng
dc.identifier.doi10.3389/fonc.2024.1220640
dc.identifier.issn2234-943X
dc.identifier.urihttp://hdl.handle.net/10400.1/26389
dc.language.isoeng
dc.peerreviewedyes
dc.publisherFrontiers Media
dc.relation.ispartofFrontiers in Oncology
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectSCCHN
dc.subjectConcurrent chemotherapy
dc.subjectCisplatin
dc.subjectCompliance
dc.subjectRadiotherapy
dc.titleRetrospective study of cisplatin plus radiotherapy toxicities in locally advanced squamous cell carcinoma of the head and neck – ReCisTT studyeng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPage1220640
oaire.citation.titleFrontiers in Oncology
oaire.citation.volume14
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameGomes
person.familyNameMacedo
person.givenNameAna
person.givenNameAna
person.identifier.ciencia-id8414-F029-8182
person.identifier.orcid0000-0002-2014-7830
person.identifier.orcid0000-0002-6978-8989
person.identifier.ridL-9912-2018
relation.isAuthorOfPublicationccbfeaf6-6451-4df3-88e2-8fc8ab6924a1
relation.isAuthorOfPublication8e798bcb-5052-47b0-a050-32f40328cc1a
relation.isAuthorOfPublication.latestForDiscovery8e798bcb-5052-47b0-a050-32f40328cc1a

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
fonc-1-1220640.pdf
Size:
706.39 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FCB2-Artigos (em revistas ou actas indexadas)
ULS_10.1-MED-Artigos